Your browser doesn't support javascript.
loading
Treatment outcomes after adjuvant radiotherapy following surgery for patients with stage I endometrial cancer.
Kim, Jiyoung; Lee, Kyung-Ja; Park, Kyung-Ran; Ha, Boram; Kim, Yi-Jun; Jung, Wonguen; Lee, Rena; Kim, Seung Cheol; Moon, Hye Sung; Ju, Woong; Kim, Yun Hwan; Lee, Jihae.
Afiliación
  • Kim J; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Lee KJ; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Park KR; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Ha B; Proton Therapy Center, National Cancer Center, Goyang, Korea.
  • Kim YJ; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Jung W; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Lee R; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Kim SC; Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Moon HS; Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Ju W; Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Kim YH; Department of Obstetrics and Gynecology, Ewha Womans University School of Medicine, Seoul, Korea.
  • Lee J; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea.
Radiat Oncol J ; 34(4): 265-272, 2016 Dec.
Article en En | MEDLINE | ID: mdl-27703126
ABSTRACT

PURPOSE:

The purpose of this study is to evaluate the treatment outcomes of adjuvant radiotherapy using vaginal brachytherapy (VB) with a lower dose per fraction and/or external beam radiotherapy (EBRT) following surgery for patients with stage I endometrial carcinoma. MATERIALS AND

METHODS:

The subjects were 43 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer who underwent adjuvant radiotherapy following surgery between March 2000 and April 2014. Of these, 25 received postoperative VB alone, while 18 received postoperative EBRT to the whole pelvis; 3 of these were treated with EBRT plus VB. The median EBRT dose was 50.0 Gy (45.0-50.4 Gy) and the VB dose was 24 Gy in 6 fractions. Tumor dose was prescribed at a depth of 5 mm from the cylinder surface and delivered twice per week.

RESULTS:

The median follow-up period for all patients was 57 months (range, 9 to 188 months). Five-year disease-free survival (DFS) and overall survival (OS) for all patients were 92.5% and 95.3%, respectively. Adjuvant radiotherapy was performed according to risk factors and stage IB, grade 3 and lymphovascular invasion were observed more frequently in the EBRT group. Five-year DFS for EBRT and VB alone were 88.1% and 96.0%, respectively (p = 0.42), and 5-year OS for EBRT and VB alone were 94.4% and 96%, respectively (p = 0.38). There was no locoregional recurrence in any patient. Two patients who received EBRT and 1 patient who received VB alone developed distant metastatic disease. Two patients who received EBRT had severe complications, one each of grade 3 gastrointestinal complication and pelvic bone insufficiency fracture.

CONCLUSION:

Adjuvant radiotherapy achieved high DFS and OS with acceptable toxicity in stage I endometrial cancer. VB (with a lower dose per fraction) may be a viable option for selected patients with early-stage endometrial cancer following surgery.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Radiat Oncol J Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Radiat Oncol J Año: 2016 Tipo del documento: Article